ReviewNature reviews. Rheumatology2026
The obesity-inflammation axis in psoriatic disease: mechanisms and therapeutic strategies.
Review in Nature reviews. Rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Association between adiposity and psoriatic arthritis beyond classical clinical predictors.Clinical rheumatology · 2026Article
- From psoriatic plaque to synovium: decoding the skin-joint axis in psoriatic arthritis.Nature reviews. Rheumatology · 2026Review
- GLP-1 receptor agonists in osteoarthritis and psoriatic disease: the missing link between obesity and inflammation?Rheumatology international · 2026Review
- Obesity, Low-Grade Chronic Inflammation, and Clinical Outcomes in Spondyloarthritis: A Translational Synthesis.Metabolites · 2026Review
- Cardiovascular Risk in Psoriatic Arthritis: Mechanisms, Risk Assessment, and Long-Term Management Implications.International journal of molecular sciences · 2026Review
- Article
- Altered Lipid Metabolism in Psoriatic Arthritis: A Comprehensive Review.Metabolites · 2026Review
- Glucagon-Like Peptide-1 Receptor Agonist Therapy Is Associated With Improvement in Psoriatic Arthritis-Related and Metabolic Outcomes: A Retrospective Analysis of Two Cohorts.Arthritis & rheumatology (Hoboken, N.J.) · 2026Article
- The impact of smoking and obesity on secukinumab effectiveness in psoriatic arthritis: real-world evidence from 1202 European patients.EULAR rheumatology open · 2026Article
- Exploratory Retrospective Assessment of Patients with Psoriasis Receiving Biological Therapy.Medicina (Kaunas, Lithuania) · 2026Article
- Psoriasis as a systemic inflammatory disease: an immune set-point framework for comorbidities and relapse.Frontiers in immunology · 2026Review
- Shared inflammatory architecture and therapeutic tensions between psoriasis and Crohn's disease.Frontiers in immunology · 2026Review
- Evaluating the psychosocial and clinical impact of diagnostic delay in psoriatic arthritis: insights from a monocentric cohort.Frontiers in immunology · 2026Article
- The night matters: sleep quality and evening chronotype associated with clinical severity of psoriasis.Frontiers in endocrinology · 2026Article
- Glucagon-like peptide-1 receptor agonists in psoriasis and psoriatic arthritis: emerging evidence and future research opportunities.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity constitutes a substantial burden in psoriatic disease that affects approximately half of patients. Importantly, increased adiposity and psoriatic disease are strongly linked, with obesity functioning as both a possible trigger and a disease modifier. Obesity predisposes individuals to develop psoriasis and is likely to drive, at least partially, the progression from psoriasis to psoriatic arthritis. For people with psoriasis or psoriatic arthritis, obesity is associated with lower rates of remission and poorer responses to treatment. Several mechanisms probably underlie this relationship, including systemic and local pro-inflammatory properties of adipose tissue, increased biomechanical stress on joints and entheses, gut dysbiosis and synergistic effects of osteoarthritis. Notably, weight loss can improve both psoriatic disease course and response to therapy; however, current approaches (such as dietary interventions or bariatric surgery) are difficult to implement. Glucagon-like peptide-1-based therapies are an effective strategy for weight loss in psoriatic disease and might even have additive disease-modifying effects to conventional immunomodulators. Although often overlooked, weight loss intervention and obesity management should be included as an integral part of psoriatic disease treatment algorithms.
Identifiers
41286370What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.